Assessing the acceptability of Norplant contraceptive in four patient populations.
The object of this study was to review the experience of Norplant implants insertion at the University of Colorado Health Sciences Center with specific attention to the potential impact of source of care and/or clinic site of of insertion. Norplant implants were inserted at four different office sites, namely, adolescent-teen, resident, certified nurse midwife, and faculty physician. The charts of all patients who had Norplant implants inserted between April 1991 and September 1992 were reviewed and we attempted to contact each patient by telephone to assess clinical course and acceptability of Norplant contraceptive. We were able to contact 254 of 414 women (61%) who had Norplant implants inserted. The average length of time since Norplant implants insertion was 13.2 months. The only significant demographic difference between groups was that the adolescent-teen patients were younger, of lower parity, less educated, and were more likely to be single than the other three groups. The overall removal proportion was 14.6%, and removal proportions were not significantly different between any of the four groups. The primary reason for removal was unacceptable bleeding (32% of removers). Only 59% of patients returned for follow-up care. Faculty physician patients were significantly more compliant with follow-up compared to adolescent-teen and resident patients (p < 0.01). Patient retention of Norplant contraceptive is unrelated to age or the clinic setting in which the device was inserted. Since similar side effects are experienced by retainers and removers, it is unclear what other factors prompt women to seek removal. Particularly in the teen and resident groups, follow-up is poor.
Department of Obstetrics and Gynecology, University of Colorado Health Sciences Center 80262, USA.
L
L
Dugoff
O W
OW
Jones
J
J
Allen-Davis
B S
BS
Hurst
W D
WD
Schlaff
D000293:Adolescent; D000328:Adult; D003271:Contraceptive Agents, Female / Q000008:administration & dosage / Q000009:adverse effects / Q000592:standards*; D004343:Drug Implants / Q000009:adverse effects / Q000592:standards; D005260:Female; D006801:Humans; D016912:Levonorgestrel / Q000008:administration & dosage / Q000009:adverse effects / Q000592:standards*; D008597:Menstrual Cycle / Q000502:physiology; D009819:Office Visits; D010342:Patient Acceptance of Health Care; D012189:Retrospective Studies
D003271:Contraceptive Agents, Female; D004343:Drug Implants; D016912:Levonorgestrel